Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim vs Filgrastim for Stem Cell Mobilization in NHL
NCT00306111Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2006
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in non-Hodgkin lymphoma (NHL), sponsored by University Hospital Tübingen. Primary endpoint: Hematopoietic recovery after autologous stem cell transplantation at 24 months. Started Jan 2006; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00306111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306111.